SkinBioTherapeutics PLC (DE:5KW)
FRANKFURT:5KW
5KW Stock Chart & Stats
€0.15
-€0.01(-6.42%)
At close: 4:00 PM EST
€0.15
-€0.01(-6.42%)
Day’s Range― - ―
52-Week Range€0.04 - €0.23
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€21.02M
Enterprise Value€21.48M
Total Cash (Recent Filing)€3.12M
Total Debt (Recent Filing)€939.16K
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Dec 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding259,168,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.69
Price to Book (P/B)4.06
Price to Sales (P/S)8.25
P/FCF Ratio-29.35
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€71.55K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthVery strong top-line growth indicates expanding market adoption of the company's microbiome skin products. Sustained high revenue growth provides runway to scale manufacturing, supports partner negotiations and demonstrates demand validation—durable drivers for 2-6 months or longer.
Conservative Balance SheetLow leverage and a healthy equity ratio reduce refinancing risk and preserve financial flexibility. This conservative capital structure supports continued R&D and commercialization efforts, enabling the company to pursue partnerships or scale without immediate solvency pressure.
Improving Gross MarginsAn improving gross margin suggests better product economics or more efficient manufacturing/sourcing. If sustained, this enhances operating leverage potential, making future profitability more attainable as revenue scales and fixed costs are spread over higher volumes.
Bears Say
Ongoing UnprofitabilityPersistent negative net income and EBIT margins mean the business is not yet self-sustaining. Continued losses can limit reinvestment, require repeated external financing, and compress management focus on achieving durable operating profitability rather than short-term growth.
Negative Operating Cash FlowNegative operating and free cash flows indicate ongoing cash burn, which reduces runway and raises dependence on new capital. Until operating cash generation turns positive, scaling manufacturing, marketing, or partner fulfilment may be constrained by liquidity rather than demand.
Partnering / Revenue Visibility RiskThe business model relies on product sales and partner/licensing deals, yet partner details and revenue mix are undisclosed. This opacity raises execution risk: sustained revenue and royalties depend on converting R&D into concrete commercial agreements.
SkinBioTherapeutics News
5KW FAQ
What was SkinBioTherapeutics PLC’s price range in the past 12 months?
SkinBioTherapeutics PLC lowest stock price was €0.04 and its highest was €0.23 in the past 12 months.
What is SkinBioTherapeutics PLC’s market cap?
SkinBioTherapeutics PLC’s market cap is €21.02M.
When is SkinBioTherapeutics PLC’s upcoming earnings report date?
SkinBioTherapeutics PLC’s upcoming earnings report date is Dec 02, 2026 which is in 174 days.
How were SkinBioTherapeutics PLC’s earnings last quarter?
Currently, no data Available
Is SkinBioTherapeutics PLC overvalued?
According to Wall Street analysts SkinBioTherapeutics PLC’s price is currently Overvalued.
Does SkinBioTherapeutics PLC pay dividends?
SkinBioTherapeutics PLC does not currently pay dividends.
What is SkinBioTherapeutics PLC’s EPS estimate?
SkinBioTherapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SkinBioTherapeutics PLC have?
SkinBioTherapeutics PLC has 259,168,670 shares outstanding.
What happened to SkinBioTherapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of SkinBioTherapeutics PLC?
Currently, no hedge funds are holding shares in DE:5KW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SkinBioTherapeutics PLC
SkinBioTherapeutics Plc is a life sciences enterprise dedicated to enhancing human health through the exploration and development of technologies that harness the power of the human microbiome. The company has developed two primary technological platforms: SkinBiotix: This innovative solution is designed to strengthen the skin's natural barrier, offer protection against infections, and promote the repair of damaged skin. AxisBiotix: Focusing on the intricate link between gut health and skin conditions, this technology aims to mitigate the symptoms experienced by individuals with psoriasis. SkinBioTherapeutics serves a wide range of industries, including cosmetic and pharmaceutical skincare, nutritional supplements, and infection control. The company maintains active collaborations with key partners: Croda Plc; the University of Manchester, for the creation of microbiome formulations that bolster the immune system; and Winclove Probiotics B.V., with whom it's developing a unique probiotic blend derived from specific bacterial species known to influence psoriasis pathways. Originally founded in 2015 as Skinbiotix Ltd, the company adopted its current name, SkinBioTherapeutics plc, in December 2016. Its operations are headquartered in Newcastle upon Tyne, United Kingdom.
Technical Analysis
ImmuPharma
―
OptiBiotix Health
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Ondine Biomedical, Inc.
―